These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 24847003)

  • 1. An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2.
    Ravichandran K; Zafar I; He Z; Doctor RB; Moldovan R; Mullick AE; Edelstein CL
    Hum Mol Genet; 2014 Sep; 23(18):4919-31. PubMed ID: 24847003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.
    Zafar I; Ravichandran K; Belibi FA; Doctor RB; Edelstein CL
    Kidney Int; 2010 Oct; 78(8):754-61. PubMed ID: 20686448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic
    Holditch SJ; Brown CN; Atwood DJ; Lombardi AM; Nguyen KN; Toll HW; Hopp K; Edelstein CL
    Am J Physiol Renal Physiol; 2019 Jul; 317(1):F187-F196. PubMed ID: 31042058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense-mediated angiotensinogen inhibition slows polycystic kidney disease in mice with a targeted mutation in Pkd2.
    Ravichandran K; Ozkok A; Wang Q; Mullick AE; Edelstein CL
    Am J Physiol Renal Physiol; 2015 Feb; 308(4):F349-57. PubMed ID: 25537744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.
    Li A; Fan S; Xu Y; Meng J; Shen X; Mao J; Zhang L; Zhang X; Moeckel G; Wu D; Wu G; Liang C
    J Cell Mol Med; 2017 Aug; 21(8):1619-1635. PubMed ID: 28244683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ablation of Long Noncoding RNA Hoxb3os Exacerbates Cystogenesis in Mouse Polycystic Kidney Disease.
    Weisser I; Eckberg K; D'Amico S; Buttram D; Aboudehen K
    J Am Soc Nephrol; 2024 Jan; 35(1):41-55. PubMed ID: 37953472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aquaporin-3 deficiency slows cyst enlargement in experimental mouse models of autosomal dominant polycystic kidney disease.
    Wang W; Geng X; Lei L; Jia Y; Li Y; Zhou H; Verkman AS; Yang B
    FASEB J; 2019 May; 33(5):6185-6196. PubMed ID: 30768374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease.
    Ravichandran K; Zafar I; Ozkok A; Edelstein CL
    Nephrol Dial Transplant; 2015 Jan; 30(1):45-53. PubMed ID: 25239638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early treatment with 2-deoxy-d-glucose reduces proliferative proteins in the kidney and slows cyst growth in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease (PKD).
    Atwood D; He Z; Miyazaki M; Hailu F; Klawitter J; Edelstein CL
    Cell Signal; 2024 Nov; 123():111351. PubMed ID: 39159908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells.
    de Stephanis L; Bonon A; Varani K; Lanza G; Gafà R; Pinton P; Pema M; Somlo S; Boletta A; Aguiari G
    Clin Exp Nephrol; 2017 Apr; 21(2):203-211. PubMed ID: 27278932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin-mediated suppression of renal cyst expansion in del34 Pkd1-/- mutant mouse embryos: an investigation of the feasibility of renal cyst prevention in the foetus.
    Stayner C; Shields J; Slobbe L; Shillingford JM; Weimbs T; Eccles MR
    Nephrology (Carlton); 2012 Nov; 17(8):739-47. PubMed ID: 22725947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease.
    Kipp KR; Rezaei M; Lin L; Dewey EC; Weimbs T
    Am J Physiol Renal Physiol; 2016 Apr; 310(8):F726-F731. PubMed ID: 26764208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
    Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
    Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease.
    Kipp KR; Kruger SL; Schimmel MF; Parker N; Shillingford JM; Leamon CP; Weimbs T
    Am J Physiol Renal Physiol; 2018 Aug; 315(2):F395-F405. PubMed ID: 29717938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuation of accelerated renal cystogenesis in Pkd1 mice by renin-angiotensin system blockade.
    Fitzgibbon WR; Dang Y; Bunni MA; Baicu CF; Zile MR; Mullick AE; Saigusa T
    Am J Physiol Renal Physiol; 2018 Feb; 314(2):F210-F218. PubMed ID: 29021226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease.
    Shillingford JM; Murcia NS; Larson CH; Low SH; Hedgepeth R; Brown N; Flask CA; Novick AC; Goldfarb DA; Kramer-Zucker A; Walz G; Piontek KB; Germino GG; Weimbs T
    Proc Natl Acad Sci U S A; 2006 Apr; 103(14):5466-71. PubMed ID: 16567633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
    Zhang X; Wang X; Xu T; Zhong S; Shen Z
    Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long noncoding RNA
    Aboudehen K; Farahani S; Kanchwala M; Chan SC; Avdulov S; Mickelson A; Lee D; Gearhart MD; Patel V; Xing C; Igarashi P
    J Biol Chem; 2018 Jun; 293(24):9388-9398. PubMed ID: 29716997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.
    Shillingford JM; Piontek KB; Germino GG; Weimbs T
    J Am Soc Nephrol; 2010 Mar; 21(3):489-97. PubMed ID: 20075061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
    PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.